<GlossaryTerm id="CDR0000658764"><TermName>urokinase plasminogen activator (uPA)-derived peptide A6</TermName><TermPronunciation>(YOOR-oh-KY-nays plaz-MIH-noh-jen AK-tih-vay-ter … deh-RIVED PEP-tide …)</TermPronunciation><TermDefinition><DefinitionText>A substance being studied in the treatment of cancer. Urokinase plasminogen activator (uPA)-derived peptide A6 is a small piece of a protein called urokinase (an enzyme that dissolves blood clots or prevents them from forming). It is a type of antiangiogenesis agent and a type of antimetastatic agent. Also called A6.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000726512" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;urokinase plasminogen activator (uPA)-derived peptide A6&quot;" language="en" id="_3"/><MediaLink ref="CDR0000726511" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;péptido A6 derivado del activador del plasminógeno urocinasa (uPa)&quot;" language="es" id="_4"/><SpanishTermName>péptido A6 derivado del activador del plasminógeno urocinasa (uPa)</SpanishTermName><SpanishTermDefinition><DefinitionText>Sustancia en estudio para el tratamiento de cáncer. El péptido A6 derivado del activador del plasminógeno urocinasa (uPa) es un trozo pequeño de una proteína que se llama urocinasa (enzima que disuelve los coágulos de sangre o impide que se formen). Es un tipo de antiangiogénico y de antimetastásico. También se llama A6.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2010-03-30</DateFirstPublished></GlossaryTerm>
